(same as original) This is a proposal to create a production center capable of implementing a pipeline that includes acquisition and evaluation of human transcription factor immunogens, production and selection of monospecific Monoclonal antibodies (mMAbs), and biochemical characterization and validation of these protein capture (affinity) reagents. We emphasize the advantages of high throughput and scalability to be achieved within our production effort, and propose the development of process improvements, thereby improving cost and quality over the duration of the award. We will maintain a degree of scientific flexibility to develop approaches to producing affinity reagents to less tractable transcription factor protein targets as they are identified in the course of production. Finally we propose a viable distribution plan consistent with NIH policies, utilizing the existing Developmental Hybridoma Monoclonal Bank, which ensures broad availability and wide accessibility for future use of the reagents with minimal constraints, consistent with achieving the goals of this funding initiative.

(same as original) A consistent set of renewable protein Capture Reagents will facilitate NIH research in all areas relevant to human health as a basic tool used by virtually all NIH funded scientists. Monoclonal antibodies will also provide the diagnostic tools and therapeutic medicines of the future.